Coya Therapeutics, Inc. Common Stock (COYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has a cash flow conversion efficiency ratio of -0.316x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.67 Billion) by net assets ($43.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see COYA market cap overview for the company's overall valuation and market capitalisation.
Coya Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Coya Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is Coya Therapeutics, Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kolon Life Science Inc
KQ:102940
|
0.007x |
|
SynAct Pharma AB
ST:SYNACT
|
-0.170x |
|
Tesoro Gold Ltd
AU:TSO
|
-0.013x |
|
Excel Cell Electronic Co Ltd
TW:2483
|
0.031x |
|
Seoyon Co Ltd
KO:007860
|
0.053x |
|
K N Kenanga Holdings Bhd
KLSE:6483
|
-0.231x |
|
GaeaSoft Corp
KQ:051160
|
0.034x |
|
Chime Ball Technology Co Ltd
TWO:1595
|
-0.018x |
Annual Cash Flow Conversion Efficiency for Coya Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Coya Therapeutics, Inc. Common Stock from 2020 to 2025. View Coya Therapeutics, Inc. Common Stock stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $43.03 Million | $-10.74 Million | -0.250x | +3.99% |
| 2024-12-31 | $39.58 Million | $-10.29 Million | -0.260x | +17.20% |
| 2023-12-31 | $35.64 Million | $-11.19 Million | -0.314x | -136.40% |
| 2022-12-31 | $-8.39 Million | $-7.24 Million | 0.862x | +180.51% |
| 2021-12-31 | $3.64 Million | $-3.90 Million | -1.071x | -2172.96% |
| 2020-12-31 | $8.30 Million | $-391.27K | -0.047x | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more